{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:18:30Z","timestamp":1787019510663,"version":"build-2736575974"},"reference-count":37,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Primary cutaneous T-cell lymphomas (CTCLs) encompass a clinically and biologically heterogeneous group of non-Hodgkin lymphomas (NHLs) defined by clonal proliferation of skin-homing malignant T lymphocytes and natural killer cells. They account for up to 75% to 80% of all cutaneous lymphomas. The current WHO-EORTC classification of cutaneous lymphomas with primary cutaneous manifestations lists 13 entities. The most common subtypes\u2014mycosis fungoides, Se\u0301zary syndrome, primary cutaneous anaplastic large cell lymphoma, and lymphomatoid papulosis\u2014which represent approximately 95% of CTCLs, will be discussed in the following review. Each entity has unique biological characteristics and clinical course. Topical and\/or systemic therapies are employed based on the stage of the disease and the tempo of progression.<\/jats:p>","DOI":"10.1182\/asheducation-2006.1.323","type":"journal-article","created":{"date-parts":[[2006,11,22]],"date-time":"2006-11-22T18:14:02Z","timestamp":1164219242000},"page":"323-330","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":26,"title":["Primary Cutaneous T-Cell Lymphomas"],"prefix":"10.1182","volume":"2006","author":[{"given":"Steven T.","family":"Rosen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Querfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111706215327200_R1","doi-asserted-by":"crossref","unstructured":"Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768\u20133785.","DOI":"10.1182\/blood-2004-09-3502"},{"key":"2019111706215327200_R2","doi-asserted-by":"crossref","unstructured":"Querfeld C, Guitart J, Kuzel TM, Rosen ST. Primary cutaneous lymphomas: a review with current treatment options. Blood Rev. 2003;17:131\u2013142.","DOI":"10.1016\/S0268-960X(03)00004-3"},{"key":"2019111706215327200_R3","doi-asserted-by":"crossref","unstructured":"Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides\/Se\u0301zary syndrome. Eur J Cancer. 2006;42:1014\u20131030.","DOI":"10.1016\/j.ejca.2006.01.025"},{"key":"2019111706215327200_R4","unstructured":"Honigsmann H, Brenner W, Rauschmeier W, Konrad K, Wolff K. Photochemotherapy for cutaneous T cell lymphoma. A follow-up study. J Am Acad Dermatol. 1984;10:238\u2013245."},{"key":"2019111706215327200_R5","doi-asserted-by":"crossref","unstructured":"Querfeld C, Rosen ST, Kuzel TM, et al. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol. 2005;141:305\u2013311.","DOI":"10.1001\/archderm.141.3.305"},{"key":"2019111706215327200_R6","doi-asserted-by":"crossref","unstructured":"Ramsay DL, Lish KM, Yalowitz CB, Soter NA. Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma. Arch Dermatol. 1992;128:931\u2013933.","DOI":"10.1001\/archderm.1992.01680170063007"},{"key":"2019111706215327200_R7","doi-asserted-by":"crossref","unstructured":"Zackheim HS, Kashani-Sabet M, Amin S. Topical corticoster-oids for mycosis fungoides. Experience in 79 patients. Arch Dermatol. 1998;134:949\u2013954.","DOI":"10.1001\/archderm.134.8.949"},{"key":"2019111706215327200_R8","doi-asserted-by":"crossref","unstructured":"Vonderheid EC, Tan ET, Kantor AF, Shrager L, Micaily B, Van Scott EJ. Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T-cell lymphoma. J Am Acad Dermatol. 1989;20:416\u2013428.","DOI":"10.1016\/S0190-9622(89)70051-7"},{"key":"2019111706215327200_R9","doi-asserted-by":"crossref","unstructured":"Zackheim HS, Epstein EH, Jr, Crain WR. Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients. J Am Acad Dermatol. 1990;22:802\u2013810.","DOI":"10.1016\/0190-9622(90)70112-U"},{"key":"2019111706215327200_R10","doi-asserted-by":"crossref","unstructured":"Breneman D, Duvic M, Kuzel TM, Yocum R, Truglia J, Stevens VJ. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol. 2002;138:325\u2013332.","DOI":"10.1001\/archderm.138.3.325"},{"key":"2019111706215327200_R11","doi-asserted-by":"crossref","unstructured":"Jones GW, Hoppe RT, Glatstein E. Electron beam treatment for cutaneous T-cell lymphoma. Hematol Oncol Clin N Am. 1995;9:1057\u20131076.","DOI":"10.1016\/S0889-8588(18)30058-3"},{"key":"2019111706215327200_R12","doi-asserted-by":"crossref","unstructured":"Ysebaert L, Truc G, Dalac S, et al. Ultimate results of radiation therapy for T1\u2013T2 mycosis fungoides (including reirradiation). Int J Radiat Oncol Biol Phys. 2004;58:1128\u20131134.","DOI":"10.1016\/j.ijrobp.2003.08.007"},{"key":"2019111706215327200_R13","doi-asserted-by":"crossref","unstructured":"Quiros PA, Jones GW, Kacinski BM, et al. Total skin electron beam therapy followed by adjuvant psoralen\/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). Int J Radiat Oncol Biol Phys. 1997;38:1027\u20131035.","DOI":"10.1016\/S0360-3016(97)00127-2"},{"key":"2019111706215327200_R14","doi-asserted-by":"crossref","unstructured":"Vonderheid EC, Thompson R, Smiles KA, Lattanand A. Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy. Arch Dermatol. 1987;123:757\u2013763.","DOI":"10.1001\/archderm.1987.01660300079016"},{"key":"2019111706215327200_R15","doi-asserted-by":"crossref","unstructured":"Kohn EC, Steis RG, Sausville EA, et al. Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Se\u0301zary syndrome. J Clin Oncol. 1990;8:155\u201360.","DOI":"10.1200\/JCO.1990.8.1.155"},{"key":"2019111706215327200_R16","unstructured":"Olsen EA, Bunn PA. 1995. Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995;9:1089\u20131107."},{"key":"2019111706215327200_R17","doi-asserted-by":"crossref","unstructured":"Kuzel, TM, Roenigk HH, Jr, Samuelson E, et al. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Se\u0301zary syndrome. J Clin Oncol. 1995;13:257\u2013263.","DOI":"10.1200\/JCO.1995.13.1.257"},{"key":"2019111706215327200_R18","doi-asserted-by":"crossref","unstructured":"Kaplan EH, Rosen ST, Norris DB, Roenigk HH, Saks RR, Bunn PA. Phase II study of recombinant human interferon-gamma for cutaneous T-cell lymphoma. J Natl Cancer Inst. 1990;82:183\u2013185.","DOI":"10.1093\/jnci\/82.3.208"},{"key":"2019111706215327200_R19","unstructured":"Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001;137:581\u2013593."},{"key":"2019111706215327200_R20","doi-asserted-by":"crossref","unstructured":"Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II\u2013III trial results. J Clin Oncol. 2001;19:2456\u20132471.","DOI":"10.1200\/JCO.2001.19.9.2456"},{"key":"2019111706215327200_R21","doi-asserted-by":"crossref","unstructured":"Querfeld C, Rosen ST, Guitart J, et al. Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous T-cell lymphoma. J Am Acad Dermatol. 2004;51:25\u201332.","DOI":"10.1016\/j.jaad.2003.11.058"},{"key":"2019111706215327200_R22","doi-asserted-by":"crossref","unstructured":"Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med. 1987;316:297\u2013303.","DOI":"10.1056\/NEJM198702053160603"},{"key":"2019111706215327200_R23","doi-asserted-by":"crossref","unstructured":"Zic JA. The treatment of cutaneous T-cell lymphoma with photopheresis. Dermatol Ther. 2003;16:337\u2013346.","DOI":"10.1111\/j.1396-0296.2003.01646.x"},{"key":"2019111706215327200_R24","doi-asserted-by":"crossref","unstructured":"Wilson LD, Jones GW, Kim D, et al. Experience with total skin electron beam therapy in combination with extracorpo-real photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides. J Am Acad Dermatol. 2000;43:54\u201360.","DOI":"10.1067\/mjd.2000.105510"},{"key":"2019111706215327200_R25","doi-asserted-by":"crossref","unstructured":"Suchin KR, Cucchiara AJ, Gottleib SL, et al Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution. Arch Dermatol2002;138:1054\u20131060.","DOI":"10.1001\/archderm.138.8.1054"},{"key":"2019111706215327200_R26","doi-asserted-by":"crossref","unstructured":"Dearden CE, Matutes E, Catovsky D. Alemtuzumab in T-cell malignancies. Med Oncol2002;19 Suppl:S27\u201332.","DOI":"10.1385\/MO:19:2S:S27"},{"key":"2019111706215327200_R27","doi-asserted-by":"crossref","unstructured":"Foss FM, Bacha P, Osann KE, Demierre MF, Bell T, Kuzel TM 2001. Biological correlates of acute hypersensitivity events with DAB(389) IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin Lymphoma2001;1:298\u2013302.","DOI":"10.3816\/CLM.2001.n.005"},{"key":"2019111706215327200_R28","doi-asserted-by":"crossref","unstructured":"Oyama Y, Guitart J, Kuzel TM, Burt RK, Rosen ST. High-dose therapy and bone marrow transplantation in cutaneous T-cell lymphoma. Hematol Oncol Clin N Am. 2003;17:1475\u20131483.","DOI":"10.1016\/S0889-8588(03)00114-X"},{"key":"2019111706215327200_R29","doi-asserted-by":"crossref","unstructured":"Forero A, Bernstein S, Gopal A, et al. Initial phase II results of SGN-30 (Anti-CD30 monoclonal antibody) in patients with refractory or recurrent systemic anaplastic large cell lymphoma (ALCL). ASCO Proc. 2005;23:6601.","DOI":"10.1200\/jco.2005.23.16_suppl.6601"},{"key":"2019111706215327200_R30","doi-asserted-by":"crossref","unstructured":"Rook AH, Zaki MH, Wysocka M, et al. The role for interleukin-12 therapy of cutaneous T cell lymphoma. Ann N Y Acad Sci. 2001;941:177\u2013184.","DOI":"10.1111\/j.1749-6632.2001.tb03721.x"},{"key":"2019111706215327200_R31","unstructured":"Olsen E, Kim Y, Kuzel TM, et al. Verinostat (suberyoylanide hydroxamic acid, SAHA) is clinically active in advanced cutaneous T-cell lymphoma: Results of a phase IIb trial. ASCO Proc. 2006;24:4225."},{"key":"2019111706215327200_R32","doi-asserted-by":"crossref","unstructured":"Wysocka M, Benoit BM, Newton S, Azzoni L, Montaner L, Rook AH. Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15. Blood. 2004;104:4142\u20134149.","DOI":"10.1182\/blood-2004-03-1190"},{"key":"2019111706215327200_R33","unstructured":"Querfeld C, Kuzel TM, Guitart J, Rosen ST. Preliminary results of a phase II study of CC-5013 (Lenalidomide, Revlimid\u2122) in patients with cutaneous T-cell lymphoma. Blood. 2005;106:936a\u2013937a."},{"key":"2019111706215327200_R34","doi-asserted-by":"crossref","unstructured":"LeBoit PE. Lymphomatoid papulosis and cutaneous CD30+ lymphoma. Am J Dermatopathol. 1996;18:221\u2013235.","DOI":"10.1097\/00000372-199606000-00001"},{"key":"2019111706215327200_R35","doi-asserted-by":"crossref","unstructured":"Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30+ lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95:3653\u20133661.","DOI":"10.1182\/blood.V95.12.3653"},{"key":"2019111706215327200_R36","doi-asserted-by":"crossref","unstructured":"Tilly H, Gaulard P, Lepage E, et al. Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome. Blood. 1997;90:3727\u20133734.","DOI":"10.1182\/blood.V90.9.3727"},{"key":"2019111706215327200_R37","doi-asserted-by":"crossref","unstructured":"French LE, Shapiro M, Junkins-Hopkins JM, Vittorio CC, Rook AH. Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy. J Am Acad Dermatol. 2001;45:914\u2013918.","DOI":"10.1067\/mjd.2001.117519"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2006\/1\/323\/1091580\/323_330ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2006\/1\/323\/1091580\/323_330ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T06:22:08Z","timestamp":1573971728000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2006\/1\/323\/19795\/Primary-Cutaneous-TCell-Lymphomas"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2006.1.323","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,1]]}}}